{"prompt": "['informed consent) will need to have all screening procedures repeated. In all cases, a', 'new informed consent must be obtained for a rescreen. A patient may not be screened', 'more than 2 times.', '5.5.1', 'Reasons for Withdrawal', 'Patients may withdraw from the study at any time and for any reason without prejudice', 'to their future medical care by the investigator or at the study site. Every effort should', 'be made to keep patients in the study. The reasons for patients not completing the', 'study will be recorded. A patient may be withdrawn from the study for any of the', 'following reasons:', '1. Does not meet the protocol inclusion criteria or meets the protocol exclusion', 'criteria.', '2. Noncompliance with the protocol.', \"3. A serious or intolerable AE that, in the investigator's opinion, requires withdrawal\", 'from the study.', '4. Laboratory safety assessments that reveal clinically significant hematological or', 'biochemical changes from baseline values, or baseline laboratory safety', 'assessments that are returned after randomization but reveal clinically significant', 'hematological or biochemical changes from screening.', '5. Symptoms or an intercurrent illness not consistent with the protocol requirements', 'or that justify withdrawal.', '6. Lost to follow-up.', '7. Other (e.g., pregnancy, development of contraindications of use of study drug).', \"8. The investigator or sponsor decide to discontinue the patient's participation in the\", 'study.', '9. The patient withdraws consent. If consent is withdrawn, the patient must be', 'questioned by the investigator or study site staff whether the withdrawal is due to', 'an AE, lack of efficacy, personal or family reasons, or whether the patient', 'withdrew consent and refused all end-of-study procedures, including refusing to', 'give a reason; these reasons must be documented in the case report form.', 'The investigator will also withdraw a patient if ITI terminates the study. Upon', 'occurrence of a serious or intolerable AE, the investigator will confer with the sponsor or', \"Medical Monitor as the sponsor's designee. If a patient is discontinued because of an\", 'AE, the event will be followed until it is resolved, stabilizes, is determined to be non-', 'Intra-Cellular Therapies, Inc. Confidential', '20 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['clinically significant, or the patient is lost to follow-up. Any patient may withdraw his or', 'her consent at any time.', '5.5.2', 'Handling of Patient Withdrawals or Patient Discontinuation of Study', 'Intervention', 'Patients are free to withdraw from the study or study treatment at any time. Patient', 'participation in the study may be stopped at any time at the discretion of the investigator', 'or at the request of the sponsor.', 'Patients who discontinue study treatment or active participation in the study will no', 'longer receive study treatment. When a patient withdraws from the study, the reason(s)', 'for withdrawal shall be recorded by the investigator on the relevant screen of the', 'electronic case report form (eCRF). Whenever possible, all patients who discontinue', 'study treatment or withdraw from the study prematurely will undergo all end-of-study', 'assessments. Patients who fail to return for final assessments will be contacted by the', 'study site (2 documented telephone calls followed by 1 registered letter or similar', 'procedures depending on regional differences) in an attempt to have them comply with', 'the protocol.', 'It is vital to obtain follow-up data on any patient withdrawn as a result of an AE or', 'serious AE (SAE). In every case, efforts must be made to undertake protocol-specified,', 'safety, follow-up procedures. All data collected from all patients, including early', 'withdrawals, will be used in the reporting and analysis of the study.', '5.6', 'Premature Termination or Suspension of Study', 'This study may be suspended or prematurely terminated by the sponsor. Written', 'notification, documenting the reason for study suspension or termination, will be', 'provided by the suspending or terminating party to the investigator, and regulatory', 'authorities. If the study is prematurely terminated or suspended, the principal', 'investigator will promptly inform the IRB/IEC and will provide the reason(s) for the', 'termination or suspension.', 'Circumstances that may warrant termination include, but are not limited to:', 'Determination of unexpected, significant, or unacceptable risk to patients.', 'Insufficient adherence to protocol requirements.', 'Data that are not sufficiently complete and/or evaluable.', 'Determination of futility.', 'Intra-Cellular Therapies, Inc. Confidential', '21 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}